Literature DB >> 6428762

Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

R G Buice, H B Niell, P Sidhu, B J Gurley.   

Abstract

The disposition kinetics of the cancer chemotherapeutic agent mitomycin C have been studied in six male patients receiving mitomycin C in combination with cisplatin and vinblastine for non-oat cell carcinoma of the lung. Following rapid IV administration of mitomycin C (10 mg/m2), serum concentration-time course data were biexponential, with biologic half-lives of 46.2 +/- 12.1 min (mean +/- SD). Pharmacokinetic analysis of data by the CSTRIP and NONLIN digital computer programs generated parameters which suggested extensive distribution (V area = 656.8 +/- 169.8 ml X kg-1, mean +/- SD) and, as reported for other alkylating agents, rapid elimination (total body clearance = 10.3 +/- 3.2 ml X kg-1 X min-1, mean +/- SD). Interpatient variations in pharmacokinetic parameters were relatively small, suggesting that close monitoring of mitomycin C therapy might be unnecessary in patients with normal renal and hepatic function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428762     DOI: 10.1007/bf00401436

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Pharmacology of mitomycin C. III. In vitro metabolism by rat liver.

Authors:  H S SCHWARTZ
Journal:  J Pharmacol Exp Ther       Date:  1962-05       Impact factor: 4.030

2.  Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue hemogenates.

Authors:  H S SCHWARTZ; F S PHILIPS
Journal:  J Pharmacol Exp Ther       Date:  1961-09       Impact factor: 4.030

3.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

4.  Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung.

Authors:  M K Samson; R L Comis; L H Baker; S Ginsberg; R J Fraile; S T Crooke
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.

Authors:  W W Sutow; J R Wilbur; T J Vietti; P Vuthibhagdee; T Fujimoto; A Watanabe
Journal:  Cancer Chemother Rep       Date:  1971-06

6.  The staging of lung cancer.

Authors:  D T Carr; C F Mountain
Journal:  Semin Oncol       Date:  1974-09       Impact factor: 4.929

7.  Determination of mitomycin C in biomedical specimens by high-performance liquid chromatography.

Authors:  A Kono; Y Hara; S Eguchi; M Tanaka; Y Matsushima
Journal:  J Chromatogr       Date:  1979-11-11

8.  Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi).

Authors:  T P Miller; L J McMahon; R B Livingston
Journal:  Cancer Treat Rep       Date:  1980

9.  Reversed-phase high-performance liquid chromatographic determination of mitomycin C in human serum.

Authors:  R G Buice; P Sidhu; B J Gurley; H B Niell
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

10.  5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  T P Butler; J S MacDonald; F P Smith; L F Smith; P V Woolley; P S Schein
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

View more
  4 in total

1.  The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

Authors:  J Verweij; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Relationship between clinical parameters and pharmacokinetics of mitomycin C.

Authors:  J Verweij; J den Hartigh; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Pharmacokinetics of mitomycin C in patients after bolus injection and chemobolisation of the hepatic artery with Spherex starch particles.

Authors:  M J Czejka; W Jäger; J Schüller
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.